ADHA’s new National Clinical Governance Centre for Digital Health, pilots from Faz and MedLuma, ChatGPT Health’s rollout and AU eRequesting Release 1.0 crystallised one clear fact in Q1 2026: vendors that ship HL7 or FHIR integrations, audit logs and clinician override paths now win big government and large‑network work. At the same time PBAC and PBS moves on GLP‑1s, Wegovy and cancer drugs forced clinical software to add eligibility checks and outcome reporting overnight.

AI becomes must-have

Governance moved from advisory to contractual. The NCGC‑DH and procurement tenders now score auditability, explainable reasoning and clinician override by default. Pilots that embedded scribes into Epic and Best Practice demonstrated integration is the differentiator, not model novelty. Who gains: EMR and enterprise vendors able to deliver HL7/FHIR‑native scribes, audit trails and local governance. Who loses: small point solutions that cannot prove lineage or ship conformance quickly. Decision forced: product teams must prioritise native governance features now or be excluded from major public and large private tenders.

Platform first purchasing

My Health Record changes, AU eRequesting, the Digital Health Implementer Hub and linked systems such as Telstra Health’s MedicalDirector integration made platform playbooks practical. Network effects favour vendors that control care workflows, lab links and device ingestion. The Potentia acquisition of HotDoc underlined private capital’s appetite for consumer‑facing scheduling and data assets. Consequence: buyers prefer vendor‑neutral data foundations and end‑to‑end platforms, pushing standalone apps into exception handling unless they join platform partners.

Funding and pricing

Policy nudges reshaped procurement priorities. PBAC’s staged approach to GLP‑1s, PBS listings for Wegovy and expanded pembrolizumab indications mean software must embed eligibility engines, registries and outcome capture to manage subsidy risk. Major funding moves such as the A$25 billion hospital uplift and the Medicare mental health LiCBT program create scale opportunities for vendors that can handle transaction volume, identity and consent. Non‑dilutive programs like ANDHealth+ also altered the financing mix for growth stage healthtech.

Limits and tradeoffs

Fast‑moving tech collided with capacity and equity constraints. Approvals for Alzheimer’s disease modifying therapies exposed MRI and specialist bottlenecks. Genomics and gender care datasets remain unrepresentative, raising real bias risk for AI deployed at scale. The hard choice for executives is balancing speed with explainability, local sequencing capacity, workforce training and Indigenous data governance. Failure to invest in these areas risks creating a two‑tier system where urban private clinics capture most gains while rural and public services fall further behind.